Lawrence E. Flaherty

8.2k total citations · 2 hit papers
117 papers, 5.4k citations indexed

About

Lawrence E. Flaherty is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Lawrence E. Flaherty has authored 117 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Oncology, 53 papers in Molecular Biology and 32 papers in Immunology. Recurrent topics in Lawrence E. Flaherty's work include Melanoma and MAPK Pathways (34 papers), Immunotherapy and Immune Responses (30 papers) and CAR-T cell therapy research (29 papers). Lawrence E. Flaherty is often cited by papers focused on Melanoma and MAPK Pathways (34 papers), Immunotherapy and Immune Responses (30 papers) and CAR-T cell therapy research (29 papers). Lawrence E. Flaherty collaborates with scholars based in United States, Canada and Australia. Lawrence E. Flaherty's co-authors include Vernon K. Sondak, John M. Kirkwood, Bruce G. Redman, Jeffrey A. Sosman, Marc S. Ernstoff, Jon Richards, Michael B. Atkins, Joseph M. Unger, Ehab Atallah and Joseph G. Ibrahim and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Lawrence E. Flaherty

115 papers receiving 5.2k citations

Hit Papers

High- and Low-Dose Interferon Alfa-2b in High-Risk Melano... 2000 2026 2008 2017 2000 2004 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190
    2000 658 citations John M. Kirkwood, Vernon K. Sondak et al. Journal of Clinical Oncology profile →
  2. Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma
    2004 598 citations Joseph I. Clark, Lawrence E. Flaherty et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lawrence E. Flaherty United States 38 3.5k 2.4k 1.7k 1.2k 615 117 5.4k
Steinar Aamdal Norway 39 4.1k 1.2× 3.0k 1.2× 2.4k 1.4× 1.1k 0.9× 461 0.7× 130 6.6k
Catriona M. McNeil Australia 31 3.2k 0.9× 1.9k 0.8× 1.1k 0.6× 698 0.6× 874 1.4× 103 4.7k
Paola Queirolo Italy 44 5.3k 1.5× 3.0k 1.2× 2.5k 1.4× 951 0.8× 662 1.1× 233 7.3k
Brendan D. Curti United States 40 3.4k 1.0× 2.1k 0.9× 2.4k 1.4× 1.9k 1.6× 935 1.5× 185 6.3k
Pier Francesco Ferrucci Italy 37 3.7k 1.1× 2.9k 1.2× 1.7k 1.0× 857 0.7× 409 0.7× 141 6.2k
Agop Y. Bedikian United States 38 3.6k 1.0× 2.6k 1.0× 1.3k 0.8× 1.0k 0.9× 403 0.7× 170 5.8k
Scot Ebbinghaus United States 36 4.0k 1.2× 2.8k 1.1× 1.7k 1.0× 975 0.8× 661 1.1× 97 6.7k
Gabriel Sica United States 38 4.0k 1.1× 2.0k 0.8× 3.0k 1.7× 1.3k 1.1× 768 1.2× 97 6.9k
Ester Simeone Italy 33 3.2k 0.9× 1.5k 0.6× 1.6k 0.9× 689 0.6× 366 0.6× 114 4.4k
April K.S. Salama United States 33 2.8k 0.8× 1.3k 0.5× 1.2k 0.7× 792 0.7× 331 0.5× 131 4.0k

Countries citing papers authored by Lawrence E. Flaherty

Since Specialization
Citations

This map shows the geographic impact of Lawrence E. Flaherty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lawrence E. Flaherty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lawrence E. Flaherty more than expected).

Fields of papers citing papers by Lawrence E. Flaherty

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lawrence E. Flaherty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lawrence E. Flaherty. The network helps show where Lawrence E. Flaherty may publish in the future.

Co-authorship network of co-authors of Lawrence E. Flaherty

This figure shows the co-authorship network connecting the top 25 collaborators of Lawrence E. Flaherty. A scholar is included among the top collaborators of Lawrence E. Flaherty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lawrence E. Flaherty. Lawrence E. Flaherty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Moon, James, T. Vincent, John P. Fruehauf, et al.. (2024). Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma. Cancer. 131(1). e35587–e35587. 2 indexed citations
2.
Milton, Denái R., William H. Sharfman, Bret Taback, et al.. (2021). An Open–Label, Randomized, Multi–Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin–2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma. OncoImmunology. 10(1). 1984059–1984059. 5 indexed citations
3.
Clark, Joseph I., Jatinder Singh, Marc S. Ernstoff, et al.. (2018). A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma. Journal for ImmunoTherapy of Cancer. 6(1). 76–76. 13 indexed citations
4.
Samlowski, Wolfram E., James Moon, Michael B. Atkins, et al.. (2017). High frequency of brain metastases after adjuvant therapy for high‐risk melanoma. Cancer Medicine. 6(11). 2576–2585. 24 indexed citations
5.
Weise, Amy & Lawrence E. Flaherty. (2014). New Options for the Adjuvant Treatment of Cutaneous Melanoma?. Current Oncology Reports. 16(11). 409–409. 10 indexed citations
6.
Ribas, Antoni, René González, Anna C. Pavlick, et al.. (2014). Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study. The Lancet Oncology. 15(9). 954–965. 201 indexed citations
7.
Flaherty, Keith T., Sandra J. Lee, Fengmin Zhao, et al.. (2012). Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma. Journal of Clinical Oncology. 31(3). 373–379. 160 indexed citations
8.
Sondak, Vernon K. & Lawrence E. Flaherty. (2011). Improved outcomes for patients with metastatic melanoma. Nature Reviews Clinical Oncology. 8(9). 513–515. 18 indexed citations
9.
Hutchins, Laura F., James Moon, Joseph I. Clark, et al.. (2007). Evaluation of interferon alpha‐2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026. Cancer. 110(10). 2269–2275. 6 indexed citations
10.
Vaishampayan, Ulka N., et al.. (2007). Phase II trial of pegylated interferon and thalidomide in malignant metastatic melanoma. Anti-Cancer Drugs. 18(10). 1221–1226. 9 indexed citations
11.
Vishnubhotla, Priya, Laura Biernat, Lawrence E. Flaherty, et al.. (2006). A Phase II Study of Docetaxel, Doxorubicin, and Infusional 5-Fluorouracil in the Treatment of Patients With Locally Advanced Breast Cancer. American Journal of Clinical Oncology. 29(5). 484–489. 2 indexed citations
12.
Flaherty, Lawrence E.. (2000). Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma.. PubMed. 6 Suppl 1. S15–20. 13 indexed citations
13.
Philip, Philip Agop & Lawrence E. Flaherty. (2000). Biochemotherapy for melanoma. Current Oncology Reports. 2(4). 314–321. 10 indexed citations
14.
Smith, David C., Bruce G. Redman, Lawrence E. Flaherty, et al.. (1998). A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology. 52(2). 257–260. 137 indexed citations
15.
Wallack, Marc K., Palma M. Shaw, Marshall M. Urist, et al.. (1997). Increased Survival of Patients Treated With a Vaccinia Melanoma Oncolysate Vaccine. Annals of Surgery. 226(2). 198–206. 37 indexed citations
16.
Pienta, Kenneth J., et al.. (1997). Phase II Chemoprevention Trial of Oral Fenretinide in Patients at Risk for Adenocarcinoma of the Prostate. American Journal of Clinical Oncology. 20(1). 36–39. 58 indexed citations
17.
Flaherty, Lawrence E., Malcolm S. Mitchell, William S. Fletcher, et al.. (1996). The Addition of Tamoxifen to Dacarbazine and Cisplatin in Metastatic Malignant Melanoma. American Journal of Clinical Oncology. 19(2). 108–113. 14 indexed citations
18.
Pienta, Kenneth J., Bruce G. Redman, Peggy S. Esper, & Lawrence E. Flaherty. (1996). A Phase II Evaluation of Oral Tamoxifen and Intermittent Intravenous Vinblastine in Hormone-Refractory Adenocarcinoma of the Prostate. American Journal of Clinical Oncology. 19(5). 500–503. 8 indexed citations
19.
Poplin, Elizabeth, Thomas H. Corbett, Lawrence E. Flaherty, et al.. (1992). Difluorodeoxycytidine (dFdC) — gemcitabine: A phase I study. Investigational New Drugs. 10(3). 165–170. 68 indexed citations
20.
Flaherty, Lawrence E., Antoinette J. Wozniak, Bruce G. Redman, et al.. (1991). 5-fluorouracil, etoposide, and cisplatin in the management of metastatic non-small cell lung cancer. Cancer. 68(5). 944–947. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Steinar Aamdal Breakdown of academic impact, for papers by Catriona M. McNeil Breakdown of academic impact, for papers by Paola Queirolo Breakdown of academic impact, for papers by Brendan D. Curti Breakdown of academic impact, for papers by Pier Francesco Ferrucci Breakdown of academic impact, for papers by Agop Y. Bedikian Breakdown of academic impact, for papers by Scot Ebbinghaus Breakdown of academic impact, for papers by Gabriel Sica Breakdown of academic impact, for papers by Ester Simeone Breakdown of academic impact, for papers by April K.S. Salama
Rankless by CCL
2026